CanBas Co., Ltd.

CanBas Co., Ltd. is a clinical-stage biopharmaceutical company focused on basic research and clinical development of anti-cancer drugs. Its lead compound CBP501, which regulates the function of the protein calmodulin, is in Phase 2 trials for non-small cell lung cancer. The company is also developing CBS9106 for patients with advanced solid tumors. Incorporated in 2000, CanBas is based in Numazu, Japan.